Hematologist-oncologist and author Vinay Prasad, MD, MPH, dismantles claims that ivermectin and fenbendazole are miracle cancer cures, while also criticizing the FDA’s approval process for expensive anti-cancer drugs…
Jimmy Ruiz, MD, reflects on his career journey in North Carolina and the transformative progress in lung cancer treatment. Early in his career, limited tools like chemotherapy presented…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
At the first virtual Immunotherapy Patient Summit, Leena Gandhi, MD, PhD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the latest immunotherapy options for patients with lung cancer. Immunotherapy…
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
